Europe Adalimumab Market - Industry Trends and Forecast to 2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	163 Pages	Data Bridge Market Research	May, 2022	DAABD17330347

Best Price Guarantee
Price	from $3,500
Length	163 Pages
Publisher	Data Bridge Market Research
Published Date	May, 2022
SKU	DAABD17330347

Europe Adalimumab Market - Industry Trends and Forecast to 2029

Europe adalimumab market is projected to register a substantial CAGR of 16.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:
Europe Adalimumab Market, By Indication (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Ulcerative Colitis, Chronic Plaque Psoriasis, Non-Infectious Intermediate and Others), Type (Biologics and Biosimilars), Dosage Strength (20MG/0.4MLG, 40MG/0.8MLG and Others), Drug Type (Branded), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, and Rest of Europe) Industry Trends and Forecast to 2029

Some of the factors driving the growth of the Europe adalimumab market are:
• Rise in prevalence of rheumatoid arthritis
• Rise in geriatric population

Market Players

The key market players for Europe adalimumab market are listed below:
• AbbVie Inc.
• Sandoz International GmbH
• Amgen Inc.
• Mylan N.V. (A subsidiary of Viatris)
• Biogen
• Celltrion Healthcare Co., Ltd.
• Fresenius Kabi SwissBioSim GmbH
• Alvotech
• Biocad
• Coherus BioSciences
• Shanghai Henlius Biotech, Inc.
• Synermore Biologics
• Prestige BioPharma Ltd.
• Janssen Global Services, LLC

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of Europe Adalimumab Market; 1.4 Limitations; 1.5 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Currency And Pricing; 2.5 Dbmr Tripod Data Validation Model; 2.6 Multivariate Modelling; 2.7 Indication Lifeline Curve; 2.8 Primary Interviews With Key Opinion Leaders; 2.9 Dbmr Market Position Grid; 2.10 Market End User Coverage Grid; 2.11 Vendor Share Analysis; 2.12 Secondary Sources; 2.13 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestel; 4.2 Porter's Five Forces Model
5 Pipeline Analysis
6 Epidemiology
7 Europe Adalimumab Market: Regulations: 7.1 Regulation In Europe:
8 Impact Of Biosimilar
9 Impact Of Covid-19 On Europe Adalimumab Market: 9.1 Overview; 9.2 Adalimumab And Covid-19; 9.3 Price Impact Of Covid-19; 9.4 Impact On Demand; 9.5 Impact On Supply Chain; 9.6 Strategic Decisions For Manufacturers; 9.7 Conclusion
10 Market Overview: 10.1 Drivers; 10.1.1 Increase In Prevalence Of Rheumatoid Arthritis; 10.1.2 Increase In The Geriatric Population; 10.1.3 Increase In The Number Of Contract Research Organizations; 10.2 Restraints; 10.2.1 High Cost Of Drugs; 10.2.2 Side Effects Of Drugs; 10.2.3 Cancer-causing Drugs; 10.3 Opportunities; 10.3.1 Rising Healthcare Expenditure; 10.3.2 Strategic Initiatives By Market Players; 10.3.3 Presence Of Product Pipeline; 10.4 Challenges; 10.4.1 Long Approval Procedure; 10.4.2 Availability Of Alternative Drugs
11 Europe Adalimumab Market, By Indication: 11.1 Overview; 11.2 Rheumatoid Arthritis; 11.3 Ankylosing Spondylitis; 11.4 Chronic Plaque Psoriasis; 11.5 Crohn's Disease; 11.6 Ulcerative Colitis; 11.7 Psoriatic Arthritis; 11.8 Juvenile Idiopathic Arthritis; 11.9 Hidradenitis Suppurativa; 11.10 Non-infectious Intermediate; 11.11 Others
12 Europe Adalimumab Market, By Type: 12.1 Overview; 12.2 Biologics; 12.3 Biosimilars; 12.3.1 Adalimumab-atto; 12.3.2 Adalimumab-adaz; 12.3.3 Adalimumab-fkjp; 12.3.4 Others
13 Europe Adalimumab Market, By Dosage Strength: 13.1 Overview; 13.2 40mg/0.8ml; 13.3 20mg/0.4ml; 13.4 Others
14 Europe Adalimumab Market, By Drug Type: 14.1 Overview; 14.2 Humira; 14.3 Amgevita; 14.4 Imraldi; 14.5 Hyrimoz; 14.6 Yuflyma; 14.7 Hulio; 14.8 Idacio
15 Europe Adalimumab Market, By Population Type: 15.1 Overview; 15.2 Adults; 15.3 Children
16 Europe Adalimumab Market, By End User: 16.1 Overview; 16.2 Hospitals; 16.3 Specialty Clinics; 16.4 Home Healthcare; 16.5 Others
17 Europe Adalimumab Market, By Distribution Channel: 17.1 Overview; 17.2 Hospital Pharmacies; 17.3 Retail Pharmacies; 17.4 Online Pharmacies; 17.5 Others
18 Europe: 18.1 Germany; 18.2 U.K.; 18.3 Italy; 18.4 France; 18.5 Spain; 18.6 Netherlands; 18.7 Switzerland; 18.8 Russia; 18.9 Belgium; 18.10 Turkey; 18.11 Austria; 18.12 Norway; 18.13 Hungary; 18.14 Lithuania; 18.15 Ireland; 18.16 Poland; 18.17 Rest Of Europe
19 Europe Adalimumab Market: Company Landscape: 19.1 Company Share Analysis: Europe
20 Swot Analysis
21 Company Profile: 21.1 Abbvie Inc.; 21.1.1 Company Snapshot; 21.1.2 Revenue Analysis; 21.1.3 Product Portfolio; 21.1.4 Recent Developments; 21.2 Amgen Inc.; 21.2.1 Company Snapshot; 21.2.2 Revenue Analysis; 21.2.3 Product Portfolio; 21.2.4 Recent Development; 21.3 Biogen; 21.3.1 Company Snapshot; 21.3.2 Revenue Analysis; 21.3.3 Product Portfolio; 21.3.4 Recent Development; 21.4 Sandoz International Gmbh; 21.4.1 Company Snapshot; 21.4.2 Revenue Analysis; 21.4.3 Product Portfolio; 21.4.4 Recent Developments; 21.5 Celltrion Healthcare Co., Ltd.; 21.5.1 Company Snapshot; 21.5.2 Revenue Analysis; 21.5.3 Product Portfolio; 21.5.4 Recent Developments; 21.6 Mylan N.V. (A Subsidiary Of Vaitris Inc.); 21.6.1 Company Snapshot; 21.6.2 Revenue Analysis; 21.6.3 Product Portfolio; 21.6.4 Recent Developments; 21.7 Alvotech; 21.7.1 Company Snapshot; 21.7.2 Product Portfolio; 21.7.3 Recent Development; 21.8 Biocad; 21.8.1 Company Snapshot; 21.8.2 Product Portfolio; 21.8.3 Recent Developments; 21.9 Coherus Biosciences; 21.9.1 Company Snapshot; 21.9.2 Product Portfolio; 21.9.3 Recent Developments; 21.10 Fresenius Kabi Swissbiosim Gmbh; 21.10.1 Company Snapshot; 21.10.2 Product Portfolio; 21.10.3 Recent Developments; 21.11 Janssen Global Services, Llc; 21.11.1 Company Snapshot; 21.11.2 Product Portfolio; 21.11.3 Recent Developments; 21.12 Prestige Biopharma Ltd.; 21.12.1 Company Snapshot; 21.12.2 Product Portfolio; 21.12.3 Recent Development; 21.13 Shanghai Henlius Biotech, Inc.; 21.13.1 Company Snapshot; 21.13.2 Product Portfolio; 21.13.3 Recent Development; 21.14 Synermore Biologics; 21.14.1 Company Snapshot; 21.14.2 Product Portfolio; 21.14.3 Recent Developments
22 Questionnaire
23 Related Reports
List Of Tables: Table 1 Europe Adalimumab Market, Pipeline Analysis; Table 2 Biosimilar Of Adalimumab Approved In The Europe; Table 3 Alternative Drug For Inflammatroy Diseases Treatment; Table 4 Europe Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 5 Europe Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 6 Europe Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 7 Europe Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 8 Europe Branded Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 9 Europe Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 10 Europe Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 11 Europe Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 12 Europe Adalimumab Market, By Country, 2020-2029 (Usd Million); Table 13 Europe Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 14 Europe Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 15 Europe Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 16 Europe Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 17 Europe Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 18 Europe Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 19 Europe Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 20 Europe Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 21 Germany Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 22 Germany Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 23 Germany Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 24 Germany Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 25 Germany Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 26 Germany Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 27 Germany Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 28 Germany Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 29 U.K. Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 30 U.K. Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 31 U.K. Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 32 U.K. Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 33 U.K. Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 34 U.K. Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 35 U.K. Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 36 U.K. Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 37 Italy Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 38 Italy Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 39 Italy Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 40 Italy Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 41 Italy Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 42 Italy Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 43 Italy Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 44 Italy Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 45 France Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 46 France Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 47 France Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 48 France Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 49 France Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 50 France Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 51 France Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 52 France Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 53 Spain Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 54 Spain Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 55 Spain Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 56 Spain Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 57 Spain Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 58 Spain Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 59 Spain Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 60 Spain Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 61 Netherlands Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 62 Netherlands Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 63 Netherlands Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 64 Netherlands Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 65 Netherlands Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 66 Netherlands Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 67 Netherlands Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 68 Netherlands Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 69 Switzerland Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 70 Switzerland Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 71 Switzerland Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 72 Switzerland Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 73 Switzerland Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 74 Switzerland Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 75 Switzerland Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 76 Switzerland Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 77 Russia Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 78 Russia Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 79 Russia Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 80 Russia Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 81 Russia Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 82 Russia Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 83 Russia Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 84 Russia Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 85 Belgium Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 86 Belgium Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 87 Belgium Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 88 Belgium Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 89 Belgium Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 90 Belgium Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 91 Belgium Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 92 Belgium Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 93 Turkey Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 94 Turkey Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 95 Turkey Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 96 Turkey Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 97 Turkey Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 98 Turkey Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 99 Turkey Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 100 Turkey Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 101 Austria Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 102 Austria Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 103 Austria Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 104 Austria Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 105 Austria Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 106 Austria Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 107 Austria Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 108 Austria Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 109 Norway Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 110 Norway Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 111 Norway Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 112 Norway Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 113 Norway Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 114 Norway Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 115 Norway Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 116 Norway Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 117 Hungary Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 118 Hungary Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 119 Hungary Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 120 Hungary Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 121 Hungary Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 122 Hungary Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 123 Hungary Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 124 Hungary Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 125 Lithuania Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 126 Lithuania Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 127 Lithuania Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 128 Lithuania Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 129 Lithuania Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 130 Lithuania Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 131 Lithuania Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 132 Lithuania Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 133 Ireland Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 134 Ireland Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 135 Ireland Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 136 Ireland Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 137 Ireland Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 138 Ireland Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 139 Ireland Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 140 Ireland Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 141 Poland Adalimumab Market, By Indication, 2020-2029 (Usd Million); Table 142 Poland Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 143 Poland Biosimilars In Adalimumab Market, By Type, 2020-2029 (Usd Million); Table 144 Poland Adalimumab Market, By Dosage Strength, 2020-2029 (Usd Million); Table 145 Poland Adalimumab Market, By Drug Type, 2020-2029 (Usd Million); Table 146 Poland Adalimumab Market, By Population Type, 2020-2029 (Usd Million); Table 147 Poland Adalimumab Market, By End User, 2020-2029 (Usd Million); Table 148 Poland Adalimumab Market, By Distribution Channel, 2020-2029 (Usd Million); Table 149 Rest Of Europe Adalimumab Market, By Indication, 2020-2029 (Usd Million)
List Of Figures: Figure 1 Europe Adalimumab Market: Segmentation; Figure 2 Europe Adalimumab Market: Data Triangulation; Figure 3 Europe Adalimumab Market: Droc Analysis; Figure 4 Europe Adalimumab Market: Regional Vs Country Market Analysis; Figure 5 Europe Adalimumab Market: Company Research Analysis; Figure 6 Europe Adalimumab Market: Interview Demographics; Figure 7 Europe Adalimumab Market: Dbmr Market Position Grid; Figure 8 Europe Adalimumab Market: Market End User Coverage Grid; Figure 9 Europe Adalimumab Market: Vendor Share Analysis; Figure 10 Europe Adalimumab Market: Segmentation; Figure 11 The Rising Geriatric Population Is Expected To Drive The Europe Adalimumab Market In The Forecast Period Of 2022 To 2029; Figure 12 Indication Segment Is Expected To Account For The Largest Share Of The Europe Adalimumab Market In 2022 & 2029; Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Europe Adalimumab Market; Figure 14 Europe Adalimumab Market: By Indication, 2021; Figure 15 Europe Adalimumab Market: By Indication, 2022-2029 (Usd Million); Figure 16 Europe Adalimumab Market: By Indication, Cagr (2022-2029); Figure 17 Europe Adalimumab Market: By Indication, Lifeline Curve; Figure 18 Europe Adalimumab Market: By Type, 2021; Figure 19 Europe Adalimumab Market: By Type, 2022-2029 (Usd Million); Figure 20 Europe Adalimumab Market: By Type, Cagr (2022-2029); Figure 21 Europe Adalimumab Market: By Type, Lifeline Curve; Figure 22 Europe Adalimumab Market: By Dosage Strength, 2021; Figure 23 Europe Adalimumab Market: By Dosage Strength, 2022-2029 (Usd Million); Figure 24 Europe Adalimumab Market: By Dosage Strength, Cagr (2022-2029); Figure 25 Europe Adalimumab Market: By Dosage Strength, Lifeline Curve; Figure 26 Europe Adalimumab Market: By Drug Type, 2021; Figure 27 Europe Adalimumab Market: By Drug Type, 2022-2029 (Usd Million); Figure 28 Europe Adalimumab Market: By Drug Type, Cagr (2022-2029); Figure 29 Europe Adalimumab Market: By Drug Type, Lifeline Curve; Figure 30 Europe Adalimumab Market: By Population Type, 2021; Figure 31 Europe Adalimumab Market: By Population Type, 2022-2029 (Usd Million); Figure 32 Europe Adalimumab Market: By Population Type, Cagr (2022-2029); Figure 33 Europe Adalimumab Market: By Population Type, Lifeline Curve; Figure 34 Europe Adalimumab Market: By End User, 2021; Figure 35 Europe Adalimumab Market: By End User, 2022-2029 (Usd Million); Figure 36 Europe Adalimumab Market: By End User, Cagr (2022-2029); Figure 37 Europe Adalimumab Market: By End User, Lifeline Curve; Figure 38 Europe Adalimumab Market: By Distribution Channel, 2021; Figure 39 Europe Adalimumab Market: By Distribution Channel, 2022-2029 (Usd Million); Figure 40 Europe Adalimumab Market: By Distribution Channel, Cagr (2022-2029); Figure 41 Europe Adalimumab Market: By Distribution Channel, Lifeline Curve; Figure 42 Europe Adalimumab Market: Snapshot (2021); Figure 43 Europe Adalimumab Market: By Country (2021); Figure 44 Europe Adalimumab Market: By Country (2022 & 2029); Figure 45 Europe Adalimumab Market: By Country (2021 & 2029); Figure 46 Europe Adalimumab Market: By Indication (2022-2029); Figure 47 Europe Adalimumab Market: Company Share 2021 (%)